Arteriosclerosis and the promise of GPIIb/IIIa inhibitors in stroke

Arquivos de Neuro-Psiquiatria

Volumn 58, Issue 1, 2000, Pages 1-10

  Saposnik, Gustavo ^a,c   Caplan, Louis R ^b  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b HARVARD MEDICAL SCHOOL   (United States)

^c NONE   (Argentina)

Author keywords

Atherogenesis; Glycoprotein IIb IIIa inhibitors; Stroke

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; CREATINE KINASE MB; DIPYRIDAMOLE; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOPEPTIDE A; LAMIFIBAN; ORBOFIBAN; SIBRAFIBAN; TICLOPIDINE; TIROFIBAN; TROPONIN I; TROPONIN T; XEMILOFIBAN;

ARTERIOSCLEROSIS; BLEEDING; CEREBROVASCULAR DISEASE; DRUG SAFETY; HEART MUSCLE ISCHEMIA; REVIEW; SECONDARY PREVENTION; STROKE; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTOPENIA; THROMBOGENESIS;

EID: 0034027393     PISSN: 0004282X     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0004-282X2000000100001     Document Type: Review

References (46)

1. Cairns JA, Gent M, Singer J, et al. Aspirin, sulfinpyrazone, or both in unstable angina: results of a Canadian multicenter trial. N Engl J Med 1985;313:1369-1375.
2. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
3. Virchow R. Ueber die akut Entzundung der Arterien. Virchows Arch Path Anat. 1847;1:272-378.
4. Foix C, Hillemand P, Ley J. Relativement an ramollissement cerebral à sa frequence et à son siege, et a importance relative des obliterations arterielles completes ou incompletes dans sa pathologie. Rev Neurol 1927;43:217-218.
5. Fisher CM. Occlusion of the internal carotid artery. Arch Neurol 1951;65:346-377.
6. Fisher CM, Ojemann RG. A clinico-pathologic study of carotid endarterectomy plaques. Rev Neurol 1986;142:573-589.
7. Fisher M, Martin A, Cosgrove M, Norris JW. The NASCET-ACAS Plaque Project. Stroke 1993;24 (Suppl 1):24-25.
8. Ogata J, Masuda J, Yutani C, Yamaguchi T. Mechanisms of cerebral artery thrombosis: a histopathological analysis on eight necropsy cases. J Neurol Neurosurg Psychiatry 1994;57:17-21.
9. Herrick JB. Clinical features of sudden obstruction of the coronary arteries. JAMA 1912; 59:2015-2020.
10. Richardson PD, Davies MJ, Born GV. Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques. Lancet 1989;2:941-944.
11. Frink RJ. Chronic ulcerated plaques: new insights into the pathogenesis of acute coronary disease. J Invasive Cardiol 1994;6:173-185.
12. Davies MJ, Bland JM, Hangartner JR, Angelini A, Thomas AC. Factors influencing the presence or absence of acute coronary artery thrombi in sudden ischaemic death. Eur Heart J 1989;10:203-208.
13. Mizuno K, Satomura K, Miyamoto A, et al. Angioscopic evaluation of coronary-artery thrombi in acute coronary syndromes. N Engl J Med. 1992;326:287-291.
14. Caplan LR. Cerebral ischemia and infarction in blacks. In Gillium RF, Gorelick PB, Cooper ES. Stroke in blacks. Basel: Karger, 1999:7-18.
15. D'Angelo A, Landi G, D'Angelo VS, et al. Protein C in stroke. Stroke 1988;19:579-583.
16. Feinberg WM, Bruck DC, Ring ME. Corrigan JJ Jr. Hemostatic markers in acute stroke. Stroke 1989;20:592-597.
17. Takano K, Yamaguchi T, Uchida K. Markers of a hypercoagulable state following acute ischemic stroke. Stroke 1992;23:194-198.
18. Fisher M, Francis R. Altered coagulation in cerebral ischemia: platelet, thrombin, and plasmin activity. Arch Neurol 1990;47:1075-1079.
19. Hass WK, Easton JD, Adams HP Jr, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. N Engl J Med 1989;321:501-507.
20. Gent M, Blakely JA, Easton JD, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke: design, organization, and baseline results. Stroke 1988;19:1203-1210.
21. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events. Lancet 1996;348:1329-1333.
22. Vane JR, Meade TW. Second European Stroke Prevention Study (ESPS 2): clinical and pharmacological implications. J Neurol Sci 1997;145:123-125.
23. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995;92:657-671.
24. Rosenschein U, Ellis SG, Yakubov SJ, Haudenschild CC, Dick RJ, Topol EJ. Histopathologic correlates of coronary lesion angiographic morphology: lessons from the directional atherectomy experience. Corn Artery Dis 1992;3:953-961.
25. Spencer F, Becker R. Platelets: structure, function, and their fundamental contribution to hemostasis and pathologic thrombosis. In Becker RC (ed). Textbook of coronary thrombosis and thrombolysis. Boston, MA: Kluwer Academic Publ. 1997:24-37.
26. Becker R. Thrombosis and the role of the platelet. Am J Cardiol 1999;83(9A):3E-6E.
27. Weisel J, Nagaswami C, Vilaire G, Bennett J. Examination of the platelet membrane glycoprotein IIb/IIIa complex and its interaction with fibrinogen and other ligands by electronic microscopy. J Biol Chem 1997;267:1663-1667.
28. Cheng GC, Loree HM, Kamm RD, Fishbein MC, Lee RT. Distribution of circumferential stress in ruptured and stable atherosclerotic lesions: a structural analysis with histopathological correlation. Circulation 1993;87:1179-1187.
29. Chen PS, Feld GK, Kriett JM, et al. Relation between upper limit of vulnerability and defibrillation threshold in humans. Circulation 1993;88:186-192.
30. Muller JE, Abela GS, Nesto RW, Tofler GH. Triggers, acute risk factors and vulnerable plaques: the lexicon of a new frontier. Am Coll Cardiol 1994;23:809-813.
31. Schomig A, Neumann FJ, Walter H, et al. Coronary stent placement in patients with acute myocardial infarction: comparison of clinical and angiographic outcome after randomization to antiplatelet or anticoagulant therapy. J Am Coll Cardiol 1997;29:28-34.
32. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-960.
33. The EPILOG Investigators: Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-1696.
34. The CAPTURE Investigators. Randomised placebo-controlled trial of abeiximab before and during coronary intervention in refractory unstable angina. Lancet 1997; 349:1429-1435.
35. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997;96:1445-1453.
36. The PRISM Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998;338:1498-1505.
37. The PRISM-PLUS Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998;338:1488-1497.
38. The PARAGON Investigators. International, randomized, controlled trial of lamifiban, heparin or both in unstable angina. Circulation 1998;97:2386-2395.
39. The IMPACT-II Investigators. Randomized placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention. Lancet 1997;349:1422-1428.
40. The ORBIT Investigators. Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet glycoprotein IIb/IIIa receptor blockade with oral xemilofiban: results of a multicenler, placebo-controlled, randomized trial. Circulation 1998;98:1268-1278.
41. The TIMI-12 Investigators. A randomised trial of an oral glycoprotein IIb/IIIa antagonist, sibrafiban, in patients post and acute coronary syndrome: results from the TIMI-12 trial. Circulation 1998;97:340-349.
42. Rebello SS, Driscoll EM, Lucchesi BR. TP-9201, a glycoprotein IIb/IIIa platelet receptor antagonist, prevents rethrombosis after successful arterial thrombolysis in the dog. Stroke 1997;28:1789-1796.
43. nd. Basilar artery rethrombosis: successful treatment with platelet glycoprotein IIa/IIIa receptor inhibitor. AJNR 1997;18:1257-1260.
44. Lempert TE, Malek AM, Halbuch VV, Phatouros CC, Dowd CF, Higashida RT. Rescue treatment of acute parent vessel thrombosis with glycoprotein IIb/IIIa inhibitor during GDC coil embolization. Stroke 1999;30:693-695.
45. Mahaffey KW, Harrington RA, Simoons ML, et al. Stroke in patients with acute coronary syndromes: incidence and outcome in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT Investigators. Circulation 199911;99:2371-2377.
46. Adams HP, Bogousslavsky J, Barnathan E, Polzer J, Leclerc JR. Preliminary safely report of a randomised, double-blinded, dose escalation trial of abciximab (ReoPro) in acute ischemic stroke. Cerebrovasc Dis 1999;9(Suppl 1):127.